Last month, gene-sequencing Goliath Illumina Corp's (ILMN-0.82%) longtime CEO Jay Flatley announced he's handing over the day to day reins at Illumina to technology guru Francis deSouza in July.

Slowing sales and profit growth and changes at the top derailed this game-changing maker of genetic sequencing machines last year. Illumina has installed over 7,500 of its gene-sequencing machines for ...

After reporting preliminary sales figures that were south of industry watchers' forecasts, shares in gene-sequencing giant Illumina Corp. toppled this week. Meanwhile, better-than-anticipated sales at ...

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (“Illumina”) (NASDAQ: ILMN) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation (“TRC”) to purchase up to 500,000 shares of ...

Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Shares of Illumina Inc. ILMN shed 1.52% to $129.56 Wednesday, on what proved to be an all-around dismal trading session for ...

Industries across the board today are facing the challenge of integrating cutting-edge technologies with established infrastructures. Companies are bringing together different data systems using data ...

Illumina Accelerator, the genomics-focused startup accelerator backed by the publicly traded genetic sequencing pioneer Illumina Corp., has picked five startups for its seventh accelerator class, the ...

After reporting preliminary sales figures that were south of industry watchers' forecasts, shares in gene-sequencing giant Illumina Corp. toppled this week. Meanwhile, better-than-anticipated sales at ...

Slowing demand and the transition of longtime CEO Jay Flatley into his new role of executive chairman caused shares in Illumina, Inc. (NASDAQ: ILMN) to slump 33.3% in 2016, according to S&P Global ...